Publisher Correction: Axicabtagene ciloleucel as second-line therapy in large B cell lymphoma ineligible for autologous stem cell transplantation: a phase 2 trial - Institut Paoli-Calmettes
Journal Articles Nature Medicine Year : 2023

Publisher Correction: Axicabtagene ciloleucel as second-line therapy in large B cell lymphoma ineligible for autologous stem cell transplantation: a phase 2 trial

Roch Houot
Emmanuel Bachy
Catherine Thieblemont
Sylvain Choquet

Abstract

In the version of this article initially published, the title of the paper, now reading "Axicabtagene ciloleucel as second-line therapy in large B cell lymphoma ineligible for autologous stem cell transplantation: a phase 2 trial," appeared incorrectly as "Axicabtagene ciloleucel in large B cell lymphoma ineligible for autologous stem cell transplantation: the phase 2 ALYCANTE trial.

Fichier principal
Vignette du fichier
41591_2023_Article_2624.pdf (502.54 Ko) Télécharger le fichier
Origin Publisher files allowed on an open archive
licence

Dates and versions

hal-04755672 , version 1 (28-10-2024)

Licence

Identifiers

Cite

Roch Houot, Emmanuel Bachy, Guillaume Cartron, François-Xavier Gros, Franck Morschhauser, et al.. Publisher Correction: Axicabtagene ciloleucel as second-line therapy in large B cell lymphoma ineligible for autologous stem cell transplantation: a phase 2 trial. Nature Medicine, 2023, 29 (10), pp.2665-2665. ⟨10.1038/s41591-023-02624-w⟩. ⟨hal-04755672⟩
0 View
0 Download

Altmetric

Share

More